Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Receivables - Net (2019 - 2025)

Historic Receivables - Net for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $6.5 million.

  • C4 Therapeutics' Receivables - Net fell 3673.73% to $6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 3673.73%. This contributed to the annual value of $3.1 million for FY2024, which is 7370.96% down from last year.
  • According to the latest figures from Q3 2025, C4 Therapeutics' Receivables - Net is $6.5 million, which was down 3673.73% from $2.2 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Receivables - Net high stood at $13.6 million for Q1 2024, and its period low was $500000.0 during Q3 2023.
  • For the 5-year period, C4 Therapeutics' Receivables - Net averaged around $4.5 million, with its median value being $3.1 million (2024).
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 7423.02% in 2022, then skyrocketed by 247556.82% in 2024.
  • Quarter analysis of 5 years shows C4 Therapeutics' Receivables - Net stood at $5.7 million in 2021, then plummeted by 74.23% to $1.5 million in 2022, then soared by 701.02% to $11.8 million in 2023, then crashed by 73.71% to $3.1 million in 2024, then skyrocketed by 110.9% to $6.5 million in 2025.
  • Its Receivables - Net was $6.5 million in Q3 2025, compared to $2.2 million in Q2 2025 and $8.0 million in Q1 2025.